Researchers identify why lung scarring persists in IPF and reverse it in models

IPF patients typically survive only 3-5 years after diagnosis, facing progressive breathlessness and loss of function from irreversible lung scarring.

For generations, idiopathic pulmonary fibrosis has been understood as a sentence without appeal — a slow hardening of the lungs that medicine could slow but never undo. Now, researchers at National Jewish Health have traced the persistence of that scarring to a single molecular signal, a protein called BCL-2 that keeps the cells responsible for fibrosis alive long past their purpose. The discovery, confirmed in human tissue and tested with an already-approved drug, raises a possibility that has long seemed out of reach: that even established lung scarring might one day be reversed.

Researchers identify why lung scarring persists in IPF and reverse it in models

Cobertura Relacionada

Recibe The Register en tu bandeja